elenabs/istock via getty images
Novavax Launches 2 Global Vaccine Programs As Educational Tools
The global vaccine programs, 'We Do Vaccines' and 'Know Our Vax,' will help provide educational information about how vaccines work and Novavax's overall global approach.
Novavax recently launched its global, unbranded vaccine programs, 'We Do Vaccines' and 'Know Our Vax' as educational efforts to help protect people's health in the fight against the coronavirus and other infectious diseases.
The 'We Do Vaccines' program helps provide educational information about the common types of vaccines and how they work, how vaccines are made and tested, and how Novavax's approach to technology makes its vaccines different.
Additionally, the 'Know Our Vax' program provides educational information about Novavax, its global approach, and its overall commitment to people everywhere.
Overall, the programs intend to inspire people to learn more about how vaccines have helped millions of lives and encourage those who are not vaccinated to consider a differentiated opinion, a Novavax spokesperson explained.
"Novavax' vaccines are built on a well-understood protein-based platform used for other vaccines for decades, and we are committed to fighting the current pandemic and aiding in overall global public health," John Trizzino, chief commercial officer and chief business officer at Novavax, said in the announcement.
"We're proud to do our part to ensure that all stakeholders have awareness about their vaccine options through the launch of educational programs such as these," Trizzino continued.
In June 2021, Novavax's COVID-19 vaccine, Nuvaxovid, was 100% effective against moderate to severe illness and 90.4% effective overall in a Phase 3 clinical trial. Nuvaxovid also elicited 91% efficacy among high-risk populations, with 62 COVID-19 cases in the placebo group and 13 COVID-19 cases in the vaccine group.
Indonesia and the Philippines were the first countries to authorize the company's vaccine in November 2021, followed by the WHO, the EU, and India in December. In January and February, South Korea, Australia, and the UK authorized Nuvaxovid.
Most recently, Novavax shipped the first vaccine doses to EU member states. The first wave of shipments includes several countries, including Germany, France, and Austria. Novavax and the European Commission also have an advanced purchase agreement for up to 100 million doses of Nuvaxovid with the option for an additional 100 million doses.
